Abiopharma

🔍 Simcere Zaiming, Inc. (Executive)

Company: NextCure, Inc. (NXTC)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Sold 30,000 shares of Common Stock at $6.16 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 308,636.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The securities reported herein were directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to have been indirectly beneficially owned by the other Reporting Persons.
• F2: Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming. Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through several intermediate companies. Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Group and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren and Tang may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described herein.
• F3: Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
• REMARKS: This Form 4 constitutes an exit filing for the Reporting Persons, as they have ceased to be beneficial owners of more than 10% of the Issuer's common stock and therefore are no longer subject to Section 16 of the Exchange Act as a result of the sale described above.